ng-350a
Gene therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 19, 2019 (NCT03852511)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06459869 | Phase 1 | Nov 15, 2024 | Akamis Bio |
| NCT05165433 | Phase 1 | Feb 28, 2022 | Merck, PsiOxus Therapeutics Ltd |
| NCT03852511 | Phase 1 | Feb 19, 2019 | PsiOxus Therapeutics Ltd, University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PsiOxus Therapeutics Ltd | For profit | 2 | 2 | 1 | 2019 |
| Akamis Bio | For profit | 1 | 1 | 1 | 2024 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1